Answers are grounded in this paper and cite their sources.
Background: GLP-1 is a peptide hormone related to the glucagon superfamily and shares a significant amino acid sequence with glucagon. The glucagon superfamily peptides are secreted from the small intestine, pancreas, brain, and peripheral nerves. Furthermore, GLP-1 controls intestinal motility and decreases gastric motility. It also has an effect of satiety, which may be attributed to its effect on the gut, but it also has a direct effect on the hypothalamic feeding centers. Aim: This study aims to assess the population awareness level regarding GLP-1 prescribing in PHCC in Abha City. Methods: A descriptive cross-sectional web-based study was used. An online questionnaire was developed by the study researchers based on a literature review and after consultation of the field experts. The questionnaire of this study included participants’ demographic data, medical history, and GLP-1 use and satisfaction. Also, it covered participants’ awareness regarding GLP-1 and its effects. Results: A total of 160 participants who used GLP-1 completed the study survey. Participants’ ages ranged from 18 to more than 50 years with a mean age of 34.8 ± 13.9 years old. Exactly 89 (55.6%) participants were females. The most used GLP-1 were Saxenda (39.4%), Ozempic (37.5%), and Trulicity (14.4%) while 8.8% used a combination of them. Exactly 127 (79.4%) participants had an overall poor awareness level regarding GLP-1 while only 33 (20.6%) had a good awareness level. Conclusion: In conclusion, the current study revealed that a significant portion of diabetic and obese persons use GLP-1 for reducing weight and controlling blood glucose levels. On the other hand, their awareness level regarding the drugs was unsatisfactory.
No takes yet. Share an insight, caveat, or question.
saleh et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: